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Summary: The purpose of this review to highlight available treatment options, their limitations, 34 
and provide direction for future investigative efforts to aid in the treatment of severe E. faecalis 35 
infections, namely infective endocarditis.   36 
 2 
ABSTRACT 37 
Enterococci, one of the most common causes of hospital-associated infections, are responsible 38 
for substantial morbidity and mortality. Enterococcus faecalis, the more common and virulent 39 
species, cause serious high-inoculum infections, namely infective endocarditis, that are 40 
associated with cardiac surgery and mortality rates that remained unchanged for the last 30 years. 41 
The best cure for these infections are observed with combination antibiotic therapy; however, 42 
optimal treatment has not been fully elucidated. It is the purpose of this review to highlight 43 
treatment options, their limitations, and provide direction for future investigative efforts to aid in 44 
the treatment of these severe infections. While ampicillin plus ceftriaxone has emerged as a 45 
preferred treatment option, mortality rates continue to be high, and from a safety standpoint, 46 
ceftriaxone, unlike other cephalosporins, promotes colonization with vancomycin resistant-47 
enterococci due to high biliary concentrations. More research is needed to improve patient 48 
outcomes from this high mortality disease.   49 
 3 
INTRODUCTION 50 
Severe enterococcal infections including infective endocarditis (IE), are associated with mortality 51 
rates as high as 20-40% and have remained unchanged for the last three decades despite 52 
advances in antimicrobial therapy.[1] Although Enterococcus faecalis and Enterococcus faecium 53 
are the two most clinically relevant species, E. faecalis accounts for approximately 97% of all IE 54 
cases predominantly impacting the elderly and patients with comorbidities.[2]  E. faecalis, unlike 55 
E. faecium, is less frequently multidrug resistant.[2] However, lack of bactericidal activity of beta-56 
lactams[3], and ability to form biofilm at higher rates than E. faecium (87-95% vs. 16-29%, 57 
respectively)[4, 5], makes treatment of E. faecalis infections particularly challenging, and may 58 
contribute to the unchanging mortality rates. Consequently, combination antimicrobial therapy is 59 
required for deep-seated E. faecalis infections, and with over 50% of isolates expressing 60 
aminoglycoside resistance, treatment options are becoming limited.[6] It is the purpose of this 61 
review to highlight available treatment options, their limitations, and provide direction for 62 
investigation of future novel combination therapies including ampicillin plus non-ceftriaxone beta-63 
lactams and daptomycin combination therapy, to further aid in the treatment of E. faecalis IE.  64 
 65 
METHODS 66 
Studies were identified by conducting PubMed, and EMBASE searches using the following 67 
keywords in one or more combinations with ‘Enterococcus faecalis’: infective, endocarditis, 68 
bacteremia, bloodstream, infection, treatment, guideline, antibiotic, combination, synergy, 69 
resistant, biofilm, clinical, diagnosis, epidemiology, in vitro, in vivo, simulated endocardial 70 
vegetation, experimental, and beta-lactamase.  Manual searches of reference lists of relevant 71 
articles found from initial searches were also conducted. No limitation was placed on publication 72 
time period. Studies were selected based on authors’ (MB and MKL) judgment of relevance to 73 
topic.  74 
 75 
 4 
ORIGIN OF COMBINATION THERAPY  76 
For serious E. faecalis infections, such as IE, bactericidal agents often as combination therapy 77 
are preferred.[2] Beta-lactam antibiotics lack bactericidal activity against enterococci when used 78 
as monotherapy, making treatment of systemic infections particularly challenging.[3] Although E. 79 
faecalis are often susceptible to ampicillin, treatment failure of 60%, and lack of bactericidal 80 
activity of cell-wall active agents (i.e. penicillin G, ampicillin, vancomycin) prompted efforts to 81 
identify combination therapies that would yield a bactericidal effect in severe infections.[1-3] 82 
Originally, penicillin or ampicillin was combined with gentamicin or streptomycin to facilitate intra-83 
cellular uptake of aminoglycosides.[3] The recognition of in vitro bactericidal synergism between 84 
beta-lactams and aminoglycosides was supported by observational clinical data and led to 85 
improvements in IE cure rates up to 75%.[3] However, rising high-level aminoglycoside resistance 86 
(HLAR), which may range to up to 63%[1, 6, 7] prompted the need for alternative therapy. 87 
Subsequently, dual beta-lactam combination therapy emerged as a viable, safe treatment option 88 
for severe infections with E. faecalis. 89 
 90 
DUAL BETA-LACTAM THERAPY 91 
In Vitro and Experimental Animal Data 92 
In 1995, Mainardi and colleagues were the first to report synergy between amoxicillin and 93 
cefotaxime in E. faecalis.[8] The results showed that the MIC for amoxicillin decreased 94 
substantially in the presence of cefotaxime, as did the MIC of cefotaxime in the presence of 95 
amoxicillin. The proposed mechanism of synergy is that partial saturation of essential penicillin 96 
binding proteins (PBPs) 4 and 5 by amoxicillin, coupled with complete saturation of non-essential 97 
PBPs 2 and 3 by cefotaxime leads to a bactericidal effect.[8] Taken together, the combination of 98 
cefotaxime and amoxicillin exploits the optimal inactivation of PBPs 2, 3, 4 and 5, thereby 99 
producing synergism on E. faecalis. Presumably the marked impairment in cell wall synthesis is 100 
the basis for this effect. 101 
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 102 
In 1999, Gavalda and colleagues further explored beta-lactam combinations by evaluating the 103 
activity of ampicillin plus ceftriaxone (AC) against E. faecalis strains with HLAR.[9] They confirmed 104 
Mainardi’s synergistic findings, and observed up to a fourfold reduction in ampicillin MIC in the 105 
presence of ceftriaxone. Furthermore, rabbits treated with AC in HLAR E. faecalis endocarditis 106 
had lower bacterial vegetation counts than rabbits treated with ampicillin alone.[9] In 2003, 107 
Gavalda et al. evaluated the utility of AC versus ampicillin plus gentamicin (AG) against E. faecalis 108 
with or without HLAR in rabbits with catheter-induced endocarditis.[10] They determined that the 109 
two combinations were comparable in efficacy, and further concluded that AC may be an 110 
alternative to AG particularly in special populations, such as patients with renal insufficiency 111 
(Table 1).[10]  112 
 113 
Human Data 114 
Clinical data have since evaluated the combination of AC against HLAR and non-HLAR E. faecalis 115 
IE.[6, 11, 12] In 2007, Gavalda et al. assessed the efficacy and safety of AC in 21 patients with 116 
HLAR, and 22 patients with non-HLAR E. faecalis IE in a multicenter, open-label clinical trial.[6] 117 
In this observational study of enterococcal IE, it was concluded that in addition to AC being a safe 118 
and effective treatment option for HLAR IE, it is a reasonable alternative for patents at risk for 119 
nephrotoxicity infected with non-HLAR organisms.[6] Subsequently, Fernandez-Hidalgo and 120 
colleagues conducted a large, non-randomized, multicenter, cohort study comparing the safety 121 
and efficacy of AC and AG in 246 episodes (159 subjects in AC group; 87 subjects in AG group) 122 
of IE caused by E. faecalis.[11] The authors concluded that the two combinations were equally 123 
effective as there was no difference in mortality while on antimicrobial treatment and during the 124 
3-month follow-up, relapse, or treatment failures requiring alternate therapy. However, patients 125 
treated with AG had significantly higher rates of adverse events (i.e. renal impairment) requiring 126 
therapy withdrawal.[11] These findings coincide with a retrospective study of prospectively 127 
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collected data that evaluated 69 episodes of IE caused by E. faecalis (30 subjects in AG group; 128 
39 subjects in AC group).[12] Similar to Fernandez-Hidalgo and colleagues, the authors did not 129 
observe a difference in in-hospital mortality or 1-year mortality between AG and AC groups, and 130 
found that patients on AG had higher rates of treatment-induced renal failure than patients 131 
receiving AC. Interestingly, the authors captured epidemiologic data that demonstrates a 132 
significant increase in IE caused by HLAR-producing E. faecalis over the course of 14 years, 133 
along with an increase in AC therapy, although the small sample size limits definite conclusions 134 
(Table 1).[12]  135 
 136 
Clinical trials are limited in IE 137 
As a result of these two clinical studies [6, 11], the 2015 national IE guidelines have been updated 138 
to recommend double beta-lactam therapy (i.e. AC) as a treatment option for HLAR infections, 139 
and a reasonable alternative to aminoglycosides for non-HLAR E. faecalis infections (Class IIa; 140 
Level of Evidence B recommendation).[2]  Of note, isolates with gentamicin resistance may be 141 
susceptible to streptomycin, and vice versa, although monitoring for streptomycin concentrations 142 
is often difficult and inefficient for clinicians since it is not available within most hospitals.  The 143 
guideline recognizes that the AC regimen has several limitations – notably 1) all data were 144 
retrospectively collected without randomization, 2) treatment recommendations were center-145 
dependent; therefore, unmeasured confounding factors as well as treatment and indication bias 146 
impacting these results cannot be ruled out and 3) gentamicin dosing and therapeutic drug 147 
monitoring were not consistent across all centers, and higher levels may have contributed to the 148 
observed increase in renal impairment.[11, 12] While data supporting the use of AC has 149 
limitations, it is important to note that studies recommending AG treatment are observational and 150 
have similar limitations.[2, 3]  151 
 152 
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As it currently stands, data providing support for optimal drug, dose and duration for the currently 153 
available treatment options remain controversial. A recent study investigated optimal gentamicin 154 
treatment duration in 84 patients with non-HLAR E. faecalis IE by comparing two groups: patients 155 
admitted prior to the Danish 2007 guideline modification versus patients admitted after guideline 156 
modification that recommended reducing gentamicin treatment duration from 4-6 weeks to 2 157 
weeks.[13]  Forty-one patients received gentamicin for a median of 28 days (IQR, 18-42), and 43 158 
patients received a median of 14 days (IQR, 7-15). There was no difference between groups for 159 
the primary outcome of 1-year event-free survival (27 [66%] vs. 29 [69%], p =0.75) measured 160 
from the end of treatment. No differences in complications, relapse, in-hospital mortality, baseline 161 
renal function, and 14-day renal function were observed between groups. However, patients 162 
receiving 14-day treatment with gentamicin therapy experienced a significantly lower reduction in 163 
renal function at discharge compared to those receiving the full course, as measured by estimated 164 
glomerular filtration rate (median -11 versus -1mL/min, p =0.009).[13] They concluded that 165 
patients may be adequately treated with two weeks of gentamicin, thereby avoiding renal 166 
impairment that is associated with long duration of aminoglycoside therapy.[13] However, this 167 
study was limited by a small sample size, and insufficient power, thereby leaving the optimal 168 
duration of therapy unclear.  169 
 170 
Interestingly, other studies demonstrate that toxicity resulting in gentamicin discontinuation 171 
occurred after approximately two weeks of treatment.[11, 12] Although Fernández-Hidalgo did not 172 
directly evaluate a shorter gentamicin treatment duration, the authors describe outcomes of 173 
gentamicin treatment failure due to adverse events, namely renal dysfunction. For the 25% of 174 
patients that failed AG therapy, the median duration of therapy with gentamicin was 14 days (IQR, 175 
12–20 days).[11] Furthermore, ten patients did not receive combination therapy after stopping 176 
gentamicin and completed their treatment course with ampicillin monotherapy.[11] Pericas et al. 177 
reported that 43% of patients in the AG group had to discontinue treatment due to toxicity; thirteen 178 
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patients were switched to AC therapy after a median of 18 days (range, 5-30 days; IQR, 15-24.5 179 
days).[12] Overall these data indicate that gentamicin toxicity is associated with longer treatment 180 
durations, and a two-week treatment course may be reasonable.   181 
 182 
CONCERN FOR DEVELOPMENT OF RESISTANCE 183 
Enterococcal resistance to beta-lactams is primarily acquired by overproduction of PBP5, and by 184 
amino acid substitutions that result in altered binding site and reduced beta-lactam interaction 185 
with PBP5.[14] Additionally, rare isolates of E. faecalis produce beta-lactamase enzymes, which 186 
in theory could compromise beta-lactam therapy against enterococcal endocarditis, and further 187 
limit the available treatment options.[3, 15]  While the impact of enterococcal beta-lactamase in 188 
low-inoculum infections is difficult to detect, the impact in high-inoculum infections, such as 189 
endocarditis, has not been fully elucidated. Data suggest that although most beta-lactamase 190 
enzymes are inducible, enterococcal beta-lactamase is produced constitutively, and at 191 
substantially lower amounts.[3, 15]  Furthermore, the enzyme remains membrane-bound, making 192 
detection of phenotypic resistance difficult unless high-inocula are used.[3, 15]  193 
 194 
CEFTRIAXONE SAFETY AND ADVERSE EVENTS CONCERNS 195 
Currently, AC combination therapy is the only tested option for the treatment of IE and bacteremia 196 
due to HLAR E. faecalis with supportive clinical data. While seemingly safe as compared to AG, 197 
safety risk associated with ceftriaxone use should not be negated. In addition to being an 198 
independent risk-factor for Clostridium difficile infections[16] numerous clinical and observational 199 
studies implicate ceftriaxone as a major risk factor for occurrence of vancomycin resistant E. 200 
faecium (VRE) infection, including bacteremia.[17, 18] This is in addition to a wealth of animal 201 
studies that have linked ceftriaxone use to promotion of gastrointestinal (GI) colonization by 202 
VRE.[19, 20] It is suggested that the high biliary excretion of ceftriaxone, with levels that exceed 203 
GI concentrations of 5,000 µg/ml, promote overgrowth of ampicillin- and vancomycin-resistant E. 204 
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faecium, whose MIC for ceftriaxone typically exceeds 10,000 µg/ml.[20] This ability of ceftriaxone 205 
to “select” for drug-resistant enterococci poses not only a risk to individual patients, but also 206 
threatens public health by contributing to developing of resistance in multiple organisms in the 207 
hospital environment. Consequently, studies investigating alternative treatment options, 208 
particularly novel beta-lactam combinations, are crucial to expand the therapeutic armamentarium 209 
against these organisms. 210 
 211 
OTHER COMBINATION THERAPIES AND FUTURE RESEARCH POTENTIAL 212 
Novel Dual Beta-Lactam Combinations 213 
Unlike ceftriaxone, other cephalosporin antibiotics, such as cefepime [19] and ceftaroline [21] do 214 
not appear to promote VRE colonization. When cefepime, cefotetan, ceftriaxone and ceftazidime 215 
were studied in the GI tract of mice, it was noted that cefepime was the least likely of the four to 216 
cause VRE colonization (no difference in colonization compared to 0.9% sodium chloride), while 217 
ceftriaxone and cefotetan reached the highest levels of colonization.[19] This is presumably a 218 
result of minimal biliary excretion of cefepime and ceftaroline, and lack of antianaerobic effect of 219 
cefepime. The combination of ampicillin plus ceftaroline demonstrated efficacy similar to AC in 220 
several in vitro pharmacodynamics studies.[22, 23] A recent in vitro study evaluated high-221 
inoculum E. faecalis against ampicillin in combination with ceftaroline, cefepime, and ceftriaxone 222 
in an in vitro pharmacodynamic model simulating human concentration-time profiles.[22] The data 223 
indicated that AC activity was similar to ampicillin plus ceftaroline, and ampicillin plus cefepime. 224 
Although ceftaroline and cefepime are not associated with VRE colonization, their utilization 225 
necessitates careful evaluation for safety and development of resistance. Dual beta-lactam 226 
therapy warrants further investigation, not only for efficacy, but also for the development of 227 
resistance and optimal dosing. 228 
 229 
Daptomycin plus Beta-Lactam Therapy  230 
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Daptomycin, a lipopeptide antibiotic with activity against Gram-positive bacteria, is of interest in 231 
treating enterococcal infections due to its activity against E. faecalis and E. faecium, including 232 
VRE. Recent data has indicated that the combination of daptomycin with beta-lactam antibiotics 233 
has synergistic effects.[24, 25] Daptomycin activity can be potentiated due to beta-lactam-234 
mediated shifts in surface charge of enterococci, causing increased uptake of the drug. While 235 
daptomycin combination therapy is more often observed in patients with resistant strains of E. 236 
faecium, case reports of successful utilization of daptomycin combination therapy in patients with 237 
severe E. faecalis infections have been published.[24, 26]  238 
 239 
Sierra-Hoffman et al. report using daptomycin (6mg/kg Q48h) in combination with ampicillin (1g 240 
Q6h) for the treatment of mitral valve IE in an 89-year-old female with stage 4 chronic kidney 241 
disease.[26] The patient was not a surgical candidate, and received 6 weeks of treatment. 242 
Subsequent surveillance blood cultures 2 weeks after cessation of therapy remained negative, 243 
and patient remained alive without signs or symptoms of IE at her 1-year follow up.[26] Although 244 
this case report used a 6mg/kg/day dose, several in vitro, in vivo and clinical outcome studies 245 
suggest higher doses (10-12mg/kg/day) are associated with better patient outcomes, particularly 246 
in severe infections [27-29]. This suggests that synergistic combinations may be daptomycin 247 
dose-sparing. Further studies exploring dosing for synergistic combinations of daptomycin and 248 
beta-lactams are warranted.  249 
 250 
Daptomycin (8 mg/kg/day) plus ceftaroline was successfully used in a case report of a 63-year-251 
old male with recurrent aortic valve endocarditis caused by HLAR E. faecalis.[24] Therapy was 252 
initiated after patient failed 6 weeks of AC therapy as evidenced by recurrent signs and symptoms 253 
of IE, and doubling in vegetation size from 5mm to 10mm. This combination was selected due to 254 
unpublished observations of synergy against several bacteremia-causing enterococci.[24] A 255 
fourfold reduction in daptomycin MIC, as well as increased daptomycin binding to the 256 
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enterococcal cell membrane in the presence of ceftaroline was observed.[24] Smith and 257 
colleagues evaluated several beta-lactams in combination with daptomycin.[25] Similar to 258 
Sakoulas et al., the authors found that ceftaroline demonstrated the greatest daptomycin MIC 259 
reduction (average 19.1+/-17.6 –fold [baseline daptomycin MIC/ daptomycin combination MIC]), 260 
followed by (in decreasing order) cefepime, ceftriaxone, ampicillin, ertapenem, cefazolin and 261 
cefotaxime.[25] Time-kill studies demonstrated synergy with daptomycin in combination with 262 
ceftaroline, ampicillin, ertapenem, ceftriaxone, and cefepime. Inconsistent synergy was noted with 263 
daptomycin and cefotaxime. No synergy was observed with daptomycin in combination with 264 
cefazolin, possibly due to differences between PBP binding profiles of beta-lactam antibiotics.[25]  265 
 266 
Fosfomycin Combinations 267 
Fosfomycin demonstrated synergy in combination with daptomycin in in vitro studies.[30] 268 
However, a follow-up in vivo aortic valve endocarditis study in rats infected with HLAR, beta-269 
lactamase producing strain of E. faecalis demonstrated no difference between the number of 270 
valves sterilized by daptomycin-alone versus daptomycin plus fosfomycin when administered as 271 
a continuous infusion through the left internal jugular vein.[31] More recent in vitro data 272 
demonstrated synergy with fosfomycin in combination with ceftriaxone[32], rifampin, tigecycline, 273 
and teicoplanin (unavailable in the US), and antagonism with ampicillin.[33] Teicoplanin is 274 
particularly interesting for further investigation as previous in vitro data demonstrate advantage 275 
over vancomycin against E. faecalis.[34] Despite in vitro synergy, current fosfomycin use is limited 276 
to uncomplicated UTIs and should not be used to treat severe infections due to limited systemic 277 
absorption when administered orally.[35] Intravenous formulations of fosfomycin are currently 278 
unavailable in the US, but may have future utility. A recent study of in vitro and in vivo (guinea pig 279 
model) use of intraperitoneal fosfomycin demonstrated promising activity against both planktonic 280 
and biofilm-forming E. faecalis when fosfomycin was used in combination with gentamicin, and 281 
daptomycin [36] demonstrating a need for further investigation. 282 
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 283 
Miscellaneous Combinations  284 
Several other in vitro and in vivo studies have been conducted evaluating combination 285 
therapy.[37-40] Synergistic combinations and their respective study designs are summarized in 286 
Table 2. Of particular interest, Arias et al. evaluated a beta-lactamase stable cephalosporin, 287 
ceftobiprole (currently unavailable in the US), and observed efficacy against bla+ and VanB-288 
resistant strains of E. faecalis in addition to synergy when used in combination with 289 
aminoglycosides.[37] Overall, ceftobiprole demonstrates high affinity for enterococcal PBPs, and 290 
requires further exploration in human subjects. 291 
 292 
CONCLUSION 293 
Although aminoglycoside-containing regimens have been the standard of enterococcal IE 294 
treatment, the rise in resistance and availability of less nephrotoxic agents have led to novel 295 
treatment options.[2] Double beta-lactam therapies have emerged as a novel strategy in the 296 
treatment of serious high-inoculum enterococcal infections due of their favorable side effect 297 
profiles, and tolerability during long-term use. Currently, AC is the only combination beta-lactam 298 
therapy supported by clinical data for the treatment of IE and bacteremia due to HLAR 299 
enterococci. However, AC combination is not without risk (i.e. resistance, VRE colonization). 300 
Therefore, there is a critical need to investigate novel drug combinations, and explore dosing 301 
strategies that optimize dose and overall exposure needed to improve efficacy and suppress the 302 
emergence of resistance.   303 
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